<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684914</url>
  </required_header>
  <id_info>
    <org_study_id>ALT-301-202</org_study_id>
    <nct_id>NCT04684914</nct_id>
  </id_info>
  <brief_title>HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)</brief_title>
  <official_title>Phase 2, Double-blind, Randomized, Placebo-controlled Study of HepTcell (Adjuvanted FP-02.2) as an Immunotherapeutic Vaccine in Treatment-naïve Patients With Inactive Chronic Hepatitis B (CHB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altimmune, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altimmune, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the antiviral effects, immunogenicity, and safety of HepTcell in&#xD;
      treatment-naive patients with inactive Chronic Hepatitis B (CHB) and low Hepatitis B surface&#xD;
      antigen (HBsAg) levels.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 26, 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients achieving virologic responses</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients achieving serologic clearance of Hepatitis B surface antigen (HBsAg)</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients achieving serologic clearance of Hepatitis B virus (HBV) DNA</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>HepTcell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose administered at intervals of 4 weeks for 6 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose administered at intervals of 4 weeks for 6 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HepTcell</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>HepTcell</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women 18 to 65 years of age, inclusive&#xD;
&#xD;
          -  Inactive CHB with documented HBsAg positivity for at least 12 months before Day 1&#xD;
&#xD;
          -  qHBsAg ≥ 10 IU/mL but ≤ 100 IU/mL in the 12 months prior to screening&#xD;
&#xD;
          -  HBV DNA ≥ 10 IU/mL at screening&#xD;
&#xD;
          -  AST, ALT, INR, albumin, total bilirubin (excluding patients with Gilbert Syndrome) and&#xD;
             direct bilirubin within normal limits at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive hepatitis B e antigen (HBeAg) at screening&#xD;
&#xD;
          -  History of a hepatitis B flare or 1-log increase in HBV DNA or HBsAg in the prior 12&#xD;
             months&#xD;
&#xD;
          -  Undetectable HBV DNA at screening&#xD;
&#xD;
          -  Fibroscan &gt; 8.5 kPA at screening, or history of hepatic fibrosis or cirrhosis (NB, a&#xD;
             Fibroscan is not required if an examination is performed within 12 months or a liver&#xD;
             biopsy was performed within 2 years before Screening and no fibrosis [F1 or greater]&#xD;
             was identified).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Altimmune CTM</last_name>
    <phone>(240) 654-1450</phone>
    <email>information@altimmune.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Central Sooner Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Gordon</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>CHB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

